Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Baird analyst Joe Vruwink maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $320 to $300.
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $300 to $303.
Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $298 to $299.
Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and lowers the price target from $310 to $300.
ResMed (NYSE:RMD) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.50 by 2.04 per...
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...
